sprite-preloader
Anzeige
Mehr »
Samstag, 20.04.2019 Börsentäglich über 12.000 News von 604 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

WKN: A0M84G ISIN: SE0002190926 Ticker-Symbol: 2I9 
Aktie:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
1-Woche-Intraday-Chart
KAROLINSKA DEVELOPMENT AB 1-Woche-Intraday-Chart

Aktuelle News zu KAROLINSKA DEVELOPMENT Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
DiKarolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-2462
STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic...
► Artikel lesen
03.04.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents1
STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that...
► Artikel lesen
KAROLINSKA DEVELOPMENT Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!

► Artikel lesen
25.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics appoints a new Chief Medical Officer4
STOCKHOLM, March 25, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that Dr. Eyal C. Attar has been appointed to a position as Senior Vice President and Chief...
► Artikel lesen
15.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical7
STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical to commercialize Promimic's proprietary Hydroxyapatite...
► Artikel lesen
07.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62194
STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of...
► Artikel lesen
27.02.Karolinska Development AB (publ): New US investor joins Series C financing of Karolinska Development's portfolio company Aprea Therapeutics3
STOCKHOLM, February 27, 2019. Karolinska Development's portfolio company Aprea Therapeutics announces today that funds managed by Janus Henderson Investors has joined its Series C financing as...
► Artikel lesen
22.02.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin3
STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics...
► Artikel lesen
12.02.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises SEK 64m and aims for listing on Nasdaq First North3
STOCKHOLM, February 12, 2019. Karolinska Development's portfolio company OssDsign announces today the closing of a private placement of SEK 64 million. Swedish private investors and the French...
► Artikel lesen
07.01.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin3
STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients...
► Artikel lesen
02.12.18Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2467
STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society...
► Artikel lesen
07.11.18Karolinska Development AB (publ): Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease3
STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational...
► Artikel lesen
01.11.18BRIEF-Karolinska Development: Study With Tafoxiparin Did Not Achieve Primary Endpoint-

► Artikel lesen
22.10.18Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug10
STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing...
► Artikel lesen
15.10.18Karolinska Development AB (publ): Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement5
STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé...
► Artikel lesen
24.09.18Karolinska Development AB (publ): Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North3
STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is...
► Artikel lesen
05.09.18Karolinska Development AB (publ): Vesalius Biocapital III Partners invests in Karolinska Development's portfolio company Forendo Pharma5
STOCKHOLM, September 5, 2018. Karolinska Development's portfolio company Forendo Pharma announces today that Vesalius Biocapital III Partners (Vesalius) joins Forendo Pharma's existing international...
► Artikel lesen
13.07.18XFRA FRA:New Instruments available on XETRA - 13.07.2018-00226
The following instruments on XETRA do have their first trading day 13.07.2018 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 13.07.2018 TrdMod InstCode Exch ISIN Name InstGrp InstType...
► Artikel lesen
04.07.18Karolinska Development AB (publ): Karolinska Development's portfolio company Forendo Pharma initiates clinical phase I study for endometriosis treatment23
STOCKHOLM, July 4, 2018. Karolinska Development's portfolio company Forendo Pharma today announces that it has received clinical trial authorization (CTA) from the Medicines and Healthcare products...
► Artikel lesen
17.06.18Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II combination study with APR-246 at hematology congress
11
STOCKHOLM, June 17, 2018. Karolinska Development's portfolio company Aprea Therapeutics presents continued positive development for the candidate drug APR-246 in patients with TP53 Mutant Myelodysplastic...
► Artikel lesen
31.05.18Karolinska Development AB (publ): Karolinska Development's portfolio company Pharmanest out-licenses Canadian rights for SHACT to Acerus3
STOCKHOLM, May 31, 2018. Karolinska Development's portfolio company Pharmanest AB has announced that it has entered into an exclusive agreement with Acerus Pharmaceuticals Corporation pertaining...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
KAROLINSKA DEVELOPMENT AB-Investoren interessieren sich auch für diese News

Unternehmen / AktienAktienkurs%Top-Nachrichten